Kite Pharma Faces Clinical Trial Patient Death

Source: The Street

May 09, 2017

Kite Pharma disclosed the death of a cancer patient from brain swelling following treatment with the company's CAR-T therapy KTE-C19.

The FDA is currently reviewing an application submitted by Kite to approve KTE-C19 for patients with advanced non-Hodgkin lymphoma.

Last year, Juno Therapeutics was forced to discontinue development of JCAR015 following the deaths of five patients due to cerebral edema.

The FDA has not placed the Kite study on clinical hold.

Read the Street articlel

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments